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Objective. To examine new investigative biomarkers and their relevance for radiographic severity in knee osteoarthritis. Methods.
The group comprised 63 patients with 73 knees examined. Patients were divided according to radiographic severity to allow
for comparison of biomarker levels. Hyaluronic acid (HA), matrix metalloproteases (MMP-1, MMP-3 and MMP-13), tissue
inhibitors of metalloproteases (TIMP-1 and TIMP-2), platelet-derived growth factor (PDGF-AB), transformed growth factor
(TGF-β), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) were
measured on synovial ﬂuid and in plasma releasate at a single time point. Principal component analysis (PCA) followed by analysis
of covariance were applied to evaluate data. Results.F o u rd i ﬀerent groups of biomarker were identiﬁed in plasma releasates. The
ﬁrst (platelet number, PDGF-AB and TGF-β) and second groups (HA and IGF-I) were related to radiographic severity, P = .005
and P = .022, respectively. The third (MMP-1 and TIMP-2) and fourth groups (MMP-3 and TIMP-1) represented the catabolic
balance, but were not associated to radiographic grading. Three diﬀerent clusters of biomarkers were found in synovial ﬂuid
but did not show any signiﬁcant association to radiographic grading. Conclusions. New imaging approaches to assess structural
deterioration and correlation with biomarker levels are warranted to advance in OA research.
Copyright © 2009 Eduardo Anitua et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Despite the vast increase in molecular knowledge accrued
during the last few years, a major breakthrough in OA
therapy has not emerged [1]. Limiting factors in current
eﬀorts are somewhat attributed to the poor understanding
of the molecular basis of disease progression and the lack
of dynamic biomarkers that reﬂect speciﬁc biological or
pathological processes [2].
Accordingly,anumberofstudieshavefocusedonﬁnding
objective tissue-speciﬁc indicators of pathogenic processes in
bothsynovialandperipheralﬂuids.Amajorbreakthroughin
this research was the ﬁnding of panels of biomarkers released
into urine and serum speciﬁcally reﬂecting the breakdown
of major cartilage macromolecules and bone turnover [3].
Other investigative biomarkers reﬂecting degradative mech-
anisms (MMPs and TIMPs) of cartilage or representing
essential cell-to-cell or cell-to-matrix signaling (Growth
Factors,GFs) in serum or plasma are also under examination
[4, 5].
The present cross-sectional study was undertaken in
order to contrast the levels of GFs in addition to hyaluronic
acid (HA), matrix metalloproteases (MMP-1, MMP-3,
MMP-13),tissueinhibitorsofmetalloproteases(TIMP-1and
T I M P - 2 )i nb o t ht h eP r e p a r a t i o nR i c hi nG r o w t hF a c t o r
(PRGF) releasate and synovial ﬂuid (SF) from patients
with OA. We hypothesized that the composition of plasma
releasate and/or SF may inﬂuence radiographic severity of
OA. Therefore, patients were divided according to radio-
graphic severity to allow for comparison of biomarker level.
2. Methods
The local Ethics Committee approved the study and all
patients signed a detailed informed consent form. The study2 International Journal of Rheumatology
was conducted with 63 consecutive patients with clinical and
radiographic evidence of knee OA, according to the ACR
criteria, [6] and with joint eﬀusion detected clinically. These
patients were a subset of a larger prospective clinical study
aiming to evaluate the eﬃcacy of PRGF for the treatment
of knee OA. Idiopathic but not secondary posttraumatic or
inﬂammatory OA were included. Patients with generalized
OA or arthroscopic lavage in the year previous to treat-
ment, or intra-articular treatment within the previous three
months were excluded. Anterior-posterior weight bearing
radiographs were scored for Ahlb¨ ack radiographic severity
grade by two trained observers in consensus.
2.1. Blood and Synovial Fluid Sampling. To obtain PRGF
from the patients, fasting venous blood was withdrawn
into 9mL tubes containing 3.8% (wt/volt) sodium citrate.
PRGF was prepared by centrifugation at 640g for 8minutes.
The platelet count in peripheral blood and PRGF was
determined using the hematological analyzer MICROS 60
from ABX (Abingdon, UK). Plasma releasates were obtained
after plasma coagulation with calcium at a ﬁnal concentra-
tion of 22.8mM followed by 1 hour incubation at 37◦C.
Longer times of incubation did not change the releasate
composition.
All patients presented joint eﬀusion, 11.5 ± 9.5cc,range
2–40cc. One aliquot was used to estimate cell counts and the
remaining volume was centrifuged at 2000g for 10minutes.
All samples were stored at −80◦C.
2.2. Measurements. HA was determined by an enzyme-
linked binding protein assay (Corgenix Inc, CO, USA). The
total amount of TIMP-1, MMP-1, MMP-13, and MMP-
3 was measured by the corresponding one step sandwich
enzyme immunoassay (EIA) from Amersham Biosciences
(UK, Buckinghamshire, England) and BioSource Interna-
tional,USA(MMP-3).Enzyme-linkedimmunosorbentassay
(ELISA) kits were used for determining PDGF-AB, VEGF,
HGF, IGF-I, and TGF-β1 concentrations (R&D Systems,
Abingdon, UK).
2.3. Statistical Analysis. Results are presented as median
and arithmetic mean ± standard deviations. The Pearson
coeﬃcient was used to evaluate the associations between
plasma and SF biomarker concentrations. Factor analysis
by the principal component (PCA) method was carried
out to determine associations between molecular markers
and reduce the data of the biochemical markers that are
correlated.ComponentswithEigenvalues>1wereextracted.
The interpretability of these markers was examined after
applying a Varimax rotation with Kaiser Normalization.
Further analysis of parametric samples was performed using
the General Linear Method (GLM) approach to ANCOVA.
Each principal factor representing combined biomarkers was
used as a dependent variable; the Ahlb¨ ack score in addition
tosexwasusedasanindependentvariable;ageandBMIwere
entered as covariables. Statistical analyses were performed
using SPSS version 15.0 (SPSS, Chicago, IL, USA).
Table 1: Levels of hyaluronic acid (HA), matrix metallopro-
teases (MMP-1, MMP-3, and MMP-13), tissue inhibitors of
metalloproteases (TIMP-1 and TIMP-2), platelet-derived growth
factor (PDGF-AB), transformed growth factor (TGF-beta), vascu-
lar endothelial growth factor (VEGF), hepatocyte growth factor
(HGF), and insulin-like growth factor (IGF-I) were measured on
knee synovial ﬂuid and in platelet-rich plasma (PRP) releasate at a
singlepointintime.Resultsareshownasmean±SD,(median),and
range (ng-pg/mL). ND not detected. ∗MMP-13 was measurable
only in 13 of the 63 patients.
PRGF Synovial ﬂuid
Leukocyte count ND <400/μL
Platelet (x106)/ m L 385 ±133 ND
(356) 217 −690
PDGF-AB (ng/mL) 15.33 ±7.48 ND
(14.19) 3600 −46725
TGF-beta1 (ng/mL) 27.02 ±11.17 0.75 ±0.56
(24.75) 8.39 −57.55 (0.62) 0.24 −3.46
VEGF (pg/mL) 200 ±142 993 ±533
(169) 10 −681 (857) 304 −2544
HGF (pg/mL) 472 ±210 672 ±445
(413) 56 −1115 (592) 212 −3768
IGF-I (ng/mL) 56.0 ±21.05 1 .5 ±20.0
(53.4) 20.0 −117.0 (53.0) 6 −100
HA (μg/mL) 72 ±66 1452 ±694
(50) 4 −367 (1385) 363 −3625
TIMP-1 (ng/mL) 48.6 ±11.5 868.6 ±511.6
(46.0) 34.0 −86.0 (720.0) 51 −3218
TIMP-2 (ng/mL) 53.0 ±24.8 120.2 ±47.0
(59.0) 3 −88 (117.0) 32 −220
MMP-1 (ng/mL) 2.55 ±1.12 24.7 ±40.6
(2.45) 0.3 −6.2 (13.0) 1.0 −250.0
MMP-3 (ng/mL) 7.17 ±3.69 571 ±494
(6.43) 1.96 −27.18 (466) 25 −2056
MMP-13
∗ (ng/mL) ND 0.056 ±0.024
(0.054) 0.033 −0.119
3. Results
The mean age of the participants was 66 ± 11 years (range
44–88) and 57% were females. Subjects had an average BMI
of 29.07 ± 4.12kg/m2 (range 22–40). The right knee was
aﬀected in 26 patients and the left in 27 while 10 patients had
both knees aﬀected. Of the 73 knee radiographs evaluated
according to Ahlb¨ ack classiﬁcation: eleven (15%) graded
Ahlb¨ a c kI ,2 2( 3 0 % )g r a d e dA h l b ¨ ack II, 27 (37%) graded
Ahlb¨ ack III, and 13 (18%) graded Ahlb¨ ack IV.
Table 1 shows the biomarker concentrations in both
plasma releasate and synovial ﬂuid.International Journal of Rheumatology 3
A marked degree of correlation (Pearson product
moment correlation coeﬃcient, r>0.5) was observed for
plasmatic IGF-I with IGF-I in synovial ﬂuid (r>0.577,
P = .000) but not for other GFs, suggesting local synthesis
of these factors and/or variable clearance kinetics.
Marked correlations were observed for platelet-secreted
growth factors (TGF-β, PDGF, HGF, and VEGF) within
plasma releasates (data not shown) while a moderate degree
of correlation (r>0.3) was observed between TGF-β and
VEGF(0.340,P = .007)andbetweenVEGFandHGF(0.265,
P = .035) within the synovium.
The levels of plasmatic but not synovial HA associated
with IGF-I in both ﬂuids, with Pearson coeﬃcients of
−0.472, P = .000 (synovial ﬂuid) and −0.415, P = .001
(plasma).
3.1. Associations of Biochemical Markers by the
Principal Component Analysis: Relationship to
Radiographic Severity
3.1.1. Plasma Releasates. The correlated biomarkers were
reduced to four independent factors explaining 70% of the
t o t a lc u m u l a t i v ev a r i a n c e( Table 2). The platelet count in
PRGF, PDGF-AB, and TGF-β 1 was loaded together in the
ﬁrst factor accounted for 24.79% of the variance. The second
factor (IGF-I and HA) explains 15.91% of the variance.
The third and fourth factors are represented by typical
biomarkers of the catabolic balance, MMP-1/TIMP-2 and
MMP-3/TIMP-1, and accounted for 14.97% and 14.68%
of the variance, respectively. To test our hypothesis that
the radiographic status entails diﬀerent biomarker levels we
used ANCOVA. In ANCOVA analyses we ascertained that
the ﬁrst (PDGF-AB and TGF-β) and the second (IGF-I
and HA) factors representing the combined biomarkers are
relevant to radiographic severity (P = .005 and P = .002,
resp.).
3.1.2. Synovial Fluid. The correlated biomarkers in synovial
ﬂuid were reduced to three factors; these together explain
51.84% of the total cumulative variance. The ﬁrst factor
comprised IGF-I and TIMP-2 and explains 20.4% of the
variance. Angiogenic signaling factors (TGF-β1, VEGF, and
HGF) accounted for 17% of the variance. HA and MMP-3
segregated in the third factor explained 14% of the variance.
Any of these factors showed a signiﬁcant connection to
Ahlb¨ ack grading.
4. Discussion
I nt h ep r e s e n ts t u d y ,w eh a v ec o m p a r e dg r o w t hf a c t o r
contents (PDGF-AB, TGF-β1, IGF-I, VEGF, and HGF) in
synovial ﬂuid and platelet-rich plasma releasate from OA
patients. The rationale for measuring GFs in OA stems
from the original therapeutic option, presently under inves-
tigation, that is based on the intra-articular application of
autologous PRGF [7]. Initially, we have compared the levels
of GFs in PRGF and synovial ﬂuid in OA to clarify the
rationale of our hypothesis. Platelets contain high levels of
Table 2: Principal component analysis coeﬃcients of independent
molecular marker factors in plasma from 63 patients with knee OA.
Molecularmarkersweregroupedintofactorsofrelatedmeasuresby
principal component analysis using a Varimax rotation with Kaiser
Normalization. Components with Eigen values >1w e r ee x t r a c t e d .
Primary components of each factor are shown in bold type.
Biomarker Factor
1234
Platelet count 0.846 −0.255 0.106 0.061
PDGF-AB 0.841 0.183 −0.186 0.177
TGF-beta1 0.853 −0.294 0.024 0.164
VEGF 0.599 0.381 0.354 −0.069
HGF 0.293 0.356 −0.489 0.505
MMP-1 0.112 −0.011 0.685 0.091
TIMP-2 −0.037 −0.014 0.828 0.213
MMP-3 −0.025 −0.058 0.138 0.832
TIMP-1 0.318 0.127 0.246 0.726
IGF-I 0.020 -0.821 0.054 0.044
HA −0.131 0.774 −0.004 0.137
TGF-β and PDGF, which may allow the possibility of using
themasavehicleforGFsupplementationwithinthecapsular
joint [8]. Additional research in animal models indicates that
TGF-β is crucial for cartilage maintenance and a deﬁciency
results in OA-like changes [9], although this issue has not
been conﬁrmed in humans.
We have also examined a further group of molecules
including HA, MMP-1, MMP-3, MMP-13, TIMP-1, and
TIMP-2. Together these molecules have been listed as inves-
tigative and/or burden biomarkers according to the BIPED
terminology [10]. Every single one may be representative of
speciﬁc molecular mechanisms primarily involving synovial
turnover, angiogenic signaling, and metabolic conditions in
OA.
Because analyses of single molecules do not reﬂect the
complexity of disease progression, a multivariate approach is
required to better illustrate the complex dynamic networks
that participate in the disease. In the present study, blood
biomarkers were investigated in PRGF releasate as an alter-
native to serum. Both are ﬂuid components that remain after
the clotting process of plasma or full blood is completed. The
former may be better in the study of PDGF and TGF-β since
it does not contain leukocytes, improving homogeneity of
the ﬂuid and reducing variability. The principal component
analysis in this ﬂuid segregated (i) platelet-secreted factors
possibly associated to angiogenesis (PDGF-AB and TGF-β),
(ii) HA and IGF-I likely related to synovium turnover and
cartilage or bone metabolism, (iii) MMP-1/TIMP2, and (iv)
MMP-3/TIMP-1,whichmayreﬂectthecatabolicstatusofthe
joint. Among the principal factors found in plasma, TGF-
β1 and PDGF showed the most consistent association with
OAseverity.AnassociationofserumTGF-β1toradiographic
severity has also been reported previously, although those
samples were collected after 12 hours of daily activities [5].
Another ﬁnding showed a signiﬁcant connection of HA
and IGF-I to radiographic severity. HA has been previously4 International Journal of Rheumatology
associated with morphological progression of knee OA [11],
whereas a systemic role for growth hormone and IGF-
I has been previously described in the pathogenesis and
progression of OA [12]. Despite these signiﬁcant ﬁndings
there are some caveats in the present study. First, plasma
and synovial ﬂuid results did not correlate. In fact, to
truly understand the interactions and inﬂuence of food
intake, circadian and activity-related variations in biomarker
concentrations could help in deﬁning more precisely the
usefulness of these biomarkers and the most appropriate
body ﬂuid for analyses.
In contrast to current agreement of the great potential
value of biomarker assessment in SF, we have only found
a single component with clear biological interpretation,
namely, the association of TGF-β1, HGF, and VEGF, which
may reﬂect angiogenesis in the synovium. It is diﬃcult to
determine why SF biomarkers did not show any association
to OA severity. It is possible that this failure may reﬂect
the limited value of standard radiography. In addition, rapid
changes in the joint in response to local perturbations along
with the rapid turnover of synovial ﬂuid and variations in
the eﬃciency of clearance from the joint compartment may
increase the inconsistency in synovial ﬂuid measurements.
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